Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-02

Clinical Trial Update: TOFAcitinib in SARS-CoV2 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial update for tofacitinib in SARS-CoV-2 related interstitial pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tofacitinib (tofacitinib)

Snippet

Sponsor: Università Politecnica delle Marche | Conditions: SARS-COv2 Related Interstitial Pneumonia | Phase 2 | Status: UNKNOWN